[
    {
        "A_B_C_Relationship": {
            "Relationship": "pancreatic cancer - CCK - gant61",
            "Result": [
                "Score: N/A"
            ],
            "Prompt": "",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/7721737/",
                    "https://pubmed.ncbi.nlm.nih.gov/37759772/",
                    "https://pubmed.ncbi.nlm.nih.gov/3966964/",
                    "https://pubmed.ncbi.nlm.nih.gov/37345148/",
                    "https://pubmed.ncbi.nlm.nih.gov/7840313/"
                ],
                "BC": []
            }
        },
        "A_C_Relationship": {
            "Relationship": "pancreatic cancer - gant61",
            "Result": [
                "Score: **+2 Point(s)** - Reasoning:\n\nUpon reviewing the provided abstracts, there is strong, consistent evidence supporting the hypothesis that **GANT61 treats pancreatic cancer**. The evidence indicates that GANT61, a small-molecule inhibitor targeting the GLI transcription factors in the Hedgehog (Hh) signaling pathway, has a beneficial effect on pancreatic cancer cells by reducing their viability and stem cell-like properties, and inducing apoptosis.\n\n**Integration of Evidence:**\n\n- **Abstract PMID: 27349387** reports that GANT61 significantly reduces the expression of stem cell marker **CD133** and sphere formation in pancreatic cancer cell lines, which are indicators of self-renewal capacity and cancer stem cell (CSC)-like properties. Notably, GANT61 **induced a greater reduction in sphere formation and cell viability** than the Smoothened (SMO) inhibitor cyclopamine, suggesting that targeting GLI transcription factors is more effective in suppressing pancreatic CSC-like cells.\n\n  Furthermore, the study demonstrates that combining GANT61 with mTOR inhibition results in an efficient reduction of cell viability and sphere formation, even in an inhibitor-resistant cell line. This combination shows **strong efficacy and wide applicability** to pancreatic CSC-like cells, indicating a **promising therapeutic strategy** for treating pancreatic cancer by targeting its stem cell population.\n\n- **Abstract PMID: 24297612** demonstrates that inhibition of the Hh pathway by GANT61 induces **autophagy** in pancreatic ductal adenocarcinoma cells. This induction of autophagy contributes to **reduced cell viability and increased apoptosis** both in vitro and in vivo. The effects of GANT61-induced autophagy on decreasing viability and promoting apoptosis were reversed by the autophagy inhibitor 3-MA, confirming that autophagy plays a critical role in the antitumor effect of GANT61. This suggests that **GANT61 exerts a therapeutic effect** by modulating autophagy pathways in pancreatic cancer cells.\n\n**Logical Reasoning and Inferences:**\n\n- The Hh signaling pathway is known to promote tumorigenesis in pancreatic cancer by enhancing cell proliferation, invasion, metastasis, and protecting against apoptosis. Inhibiting this pathway is therefore a logical therapeutic strategy.\n\n- GANT61 targets GLI transcription factors, which are downstream effectors in the Hh pathway. By inhibiting GLI, GANT61 effectively suppresses the transcription of genes that promote tumorigenic properties in pancreatic cancer cells.\n\n- The consistent finding across studies that GANT61 reduces cell viability, decreases stem cell-like properties, and induces apoptosis provides a logical and mechanistic basis for its therapeutic potential in treating pancreatic cancer.\n\n**Assessment of Interaction Nature and Directionality:**\n\n- The interaction between GANT61 and pancreatic cancer cells is **beneficial** relative to the proposed hypothesis. GANT61 exerts an **antitumor effect** by inhibiting the Hh/GLI signaling pathway, leading to decreased viability and stemness of pancreatic cancer cells.\n\n- There are **no reports** in the provided abstracts indicating that GANT61 has detrimental effects on pancreatic cancer cells or that it promotes tumorigenesis.\n\n**Addressing Contradictory Evidence:**\n\n- There is **no contradictory evidence** in the provided abstracts that challenges the hypothesis. All findings consistently indicate a therapeutic benefit of GANT61 in pancreatic cancer models.\n\n**Conclusion According to Scoring Guideline:**\n\n- According to the scoring guidelines, a score of **+2** is assigned when the hypothesis is **supported by consistent evidence** indicating that the interaction between pancreatic cancer and GANT61 **aligns with the proposed outcome**, with no significant contradictory evidence.\n\n- The evidence from **multiple abstracts** demonstrates that GANT61 effectively reduces pancreatic cancer cell viability, decreases stem cell-like properties, and induces apoptosis through inhibition of the Hh/GLI signaling pathway.\n\n- Therefore, the **assigned score is +2**, as the hypothesis that \"GANT61 treats pancreatic cancer\" is **strongly supported** by the consistent and beneficial interactions detailed in the provided abstracts."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 19860666\nTitle: Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation.\nAbstract: Hedgehog signaling is aberrantly activated in glioma, medulloblastoma, basal cell carcinoma, lung cancer, esophageal cancer, gastric cancer, pancreatic cancer, breast cancer, and other tumors. Hedgehog signals activate GLI family members via Smoothened. RTK signaling potentiates GLI activity through PI3K-AKT-mediated GSK3 inactivation or RAS-STIL1-mediated SUFU inactivation, while GPCR signaling to Gs represses GLI activity through adenylate cyclase-mediated PKA activation. GLI activators bind to GACCACCCA motif to regulate transcription of GLI1, PTCH1, PTCH2, HHIP1, MYCN, CCND1, CCND2, BCL2, CFLAR, FOXF1, FOXL1, PRDM1 (BLIMP1), JAG2, GREM1, and Follistatin. Hedgehog signals are fine-tuned based on positive feedback loop via GLI1 and negative feedback loop via PTCH1, PTCH2, and HHIP1. Excessive positive feedback or collapsed negative feedback of Hedgehog signaling due to epigenetic or genetic alterations leads to carcinogenesis. Hedgehog signals induce cellular proliferation through upregulation of N-Myc, Cyclin D/E, and FOXM1. Hedgehog signals directly upregulate JAG2, indirectly upregulate mesenchymal BMP4 via FOXF1 or FOXL1, and also upregulate WNT2B and WNT5A. Hedgehog signals induce stem cell markers BMI1, LGR5, CD44 and CD133 based on cross-talk with WNT and/or other signals. Hedgehog signals upregulate BCL2 and CFLAR to promote cellular survival, SNAI1 (Snail), SNAI2 (Slug), ZEB1, ZEB2 (SIP1), TWIST2, and FOXC2 to promote epithelial-to-mesenchymal transition, and PTHLH (PTHrP) to promote osteolytic bone metastasis. KAAD-cyclopamine, Mu-SSKYQ-cyclopamine, IPI-269609, SANT1, SANT2, CUR61414 and HhAntag are small-molecule inhibitors targeted to Smoothened, GANT58, GANT61 to GLI1 and GLI2, and Robot-nikinin to SHH. Hedgehog signaling inhibitors should be used in combination with RTK inhibitors, GPCR modulators, and/or irradiation for cancer therapy.\n\n===END OF ABSTRACT=== PMID: 27349387\nTitle: Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition.\nAbstract: Pancreatic cancer is one of the most lethal malignancies. The innovative treatments are required and now the cancer stem cells (CSCs) are expected to be an effective target for novel therapies. Therefore we investigated the significance of hedgehog (Hh) signaling in the maintenance of CSC-like properties of pancreatic cancer cells, in order to discover the key molecules controlling their unique properties. Human pancreatic cancer cell lines, Capan-1, PANC-1, MIA PaCa-2 and Capan-1\u00a0M9 were used for our experiments in DMEM/F12 medium containing 10\u00a0% fetal bovine serum. Sphere formation assay, immunofluorescence staining, flow cytometric analysis and MTT cell viability assay were performed to investigate molecular signals and the efficacy in the treatment of pancreatic cancer cells. Inhibition of the Hh pathway significantly reduced the expression of stem cell marker CD133 and sphere formation, an index of self-renewal capacity, demonstrating the suppression of CSC-like properties. Moreover, the GLI inhibitor GANT61 induced greater reduction in sphere formation and cell viability of pancreatic cancer cells than the smoothened (SMO) inhibitor cyclopamine. This suggests that GLI transcription factors, but not SMO membrane protein, are the key molecules in the Hh pathway. The treatment using GANT61 in combination with the inhibition of mTOR, which is another key molecule in pancreatic CSCs, resulted in the efficient reduction of cell viability and sphere formation of an inhibitor-resistant cell line, showing the strong efficacy and wide range applicability to pancreatic CSC-like cells. Thus, this novel combination treatment could be useful for the control of pancreatic cancer by targeting pancreatic CSCs. This is the first report of the efficient elimination of pancreatic cancer stem-like cells by the double blockage of Hh/GLI and mTOR signaling.\n\n===END OF ABSTRACT=== PMID: 20024066\nTitle: Small-molecule modulators of the Sonic Hedgehog signaling pathway.\nAbstract: Sonic hedgehog (Shh) is the most widely characterized of the three vertebrate Hedgehog homologs, and is essential for proper embryonic development. Shh binds to its receptor, Patched (Ptch1), resulting in the de-repression of Smoothened (Smo). This leads to the activation of Gli2, which regulates the transcription of target genes that include Gli1 and Ptch1. Several synthetic and naturally occurring small-molecule modulators of Smo have been discovered. Shh-signaling antagonists that bind to Smo include cyclopamine, SANT1, and Cur-61414. Shh signaling agonists that bind to Smo include the synthetic small molecules purmorphamine and SAG. Small molecules that inhibit Shh signaling downstream of Smo, GANT58 and GANT61 have also been reported. Robotnikinin inhibits the Shh pathway by directly targeting Shh. Although progress has been made in understanding and modulating Shh signaling, fundamental aspects of Shh signal transduction remain obscure, including the mechanism(s) whereby Ptch1 regulates Smo activity. Small-molecule modulators of Shh signaling provide a means to regulate the activity of a pathway implicated in medulloblastoma, basal cell carcinoma (BCC), pancreatic cancer, prostate cancer and developmental disorders. Several Shh inhibitors have not succeeded in the clinic for unknown reasons, but clinical trials in BCC and pancreatic cancer with the promising Smo antagonists GDC-0449 and IPI-926 are currently underway.\n\n===END OF ABSTRACT=== PMID: 24297612\nTitle: Inhibition of the Hedgehog pathway induces autophagy in pancreatic ductal adenocarcinoma cells.\nAbstract: The HH signaling pathway is a 'core' signal transduction pathway in pancreatic cancer that promotes the tumorigenesis of pancreatic cancers via enhancing cell proliferation, increasing invasion and metastasis and protecting against apoptosis. In the present study, we found that HH signaling regulates autophagy in pancreatic cancer cells. Activation of HH signaling inhibits autophagy, while inhibition of the HH pathway induces autophagy. Although the role of autophagy in cell survival and apoptosis may depend on tumor type and the microenvironment, our data clearly demonstrated that GANT61-induced autophagy contributed to reduced viability and increased apoptosis in pancreatic cancer cells both in vivo and in vitro, and these effects were reversed by the autophagy inhibitor, 3-MA. We propose that HH signaling by regulating autophagy plays an important role in determining the cellular response to HH-targeted therapy in pancreatic cancer and further investigation of the interaction between autophagy and HH signaling is particularly important.\n\n===END OF ABSTRACT===\n\n.\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis: gant61 treats pancreatic cancer., which posits an interaction between pancreatic cancer and gant61. Use only the provided abstracts from PubMed that mention pancreatic cancer and gant61 to inform your analysis.\n\nYour evaluation should:\n\n\u2022 Integrate evidence from all abstracts to discern how pancreatic cancer and gant61 might be interconnected.\n\u2022 Employ logical reasoning, drawing logical inferences where appropriate, based on the interaction between pancreatic cancer and gant61.\n\u2022 Assess the nature and directionality of the interaction, determining whether they are beneficial or detrimental to the proposed outcome in the hypothesis.\n\u2022 Be vigilant for any evidence that contradicts or challenges the hypothesis, explicitly addressing any contradictions in your reasoning.\n\u2022 Avoid inferring effects not supported by the texts, ensuring that all conclusions are grounded in the provided information.\n\u2022 Ensure that your scoring reflects an unbiased assessment based solely on the provided evidence, considering logical inferences from evidence.\n\n**Examples:**\n\n\u2022 **Example 1: Strong Positive Outcome**\n  - **Hypothesis:** gant61 treats pancreatic cancer.\n  - **Evidence:**\n     Multiple abstracts show that gant61 **inhibits processes that worsen pancreatic cancer**.\n     Inhibition of these processes significantly **improves pancreatic cancer** in various contexts.\n  - **Logical Conclusion:**\n     Since gant61 inhibits harmful processes, and inhibition of these processes improves pancreatic cancer, there is strong, consistent evidence supporting the hypothesis.\n  - **Scoring:**\n     The interactions are consistent and beneficial.\n     **Assigned Score:** **+2**\n\n\u2022 **Example 2: Likely Positive Outcome**\n  - **Hypothesis:** gant61 treats pancreatic cancer.\n  - **Evidence:**\n     Some abstracts suggest that gant61 **may activate beneficial pathways affecting pancreatic cancer**.\n     Activation of these pathways might improve pancreatic cancer, but evidence is limited or not robust.\n  - **Logical Conclusion:**\n     There is evidence indicating potential beneficial interaction, but some uncertainty exists due to limited data or minor contradictions.\n  - **Scoring:**\n     The hypothesis is likely supported by the evidence.\n     **Assigned Score:** **+1**\n\n\u2022 **Example 3: Neutral Outcome**\n  - **Hypothesis:** gant61 treats pancreatic cancer.\n  - **Evidence:**\n     Abstracts provide insufficient or inconclusive information about the interaction.\n     Evidence might be mixed or does not directly relate to the hypothesis.\n  - **Logical Conclusion:**\n     There is not enough evidence to support or refute the hypothesis.\n  - **Scoring:**\n     The evidence is inconclusive.\n     **Assigned Score:** **0**\n\n\u2022 **Example 4: Likely Negative Outcome**\n  - **Hypothesis:** gant61 treats pancreatic cancer.\n  - **Evidence:**\n     Some abstracts indicate that gant61 **activates processes that worsen pancreatic cancer**.\n     Activation of these processes may worsen pancreatic cancer, but evidence is limited or not definitive.\n  - **Logical Conclusion:**\n     There is substantial indication that the interaction may be detrimental to the proposed outcome, but some uncertainty or exceptions exist.\n  - **Scoring:**\n     The hypothesis is likely refuted based on the evidence.\n     **Assigned Score:** **-1**\n\n\u2022 **Example 5: Strong Negative Outcome**\n  - **Hypothesis:** gant61 treats pancreatic cancer.\n  - **Evidence:**\n     Multiple abstracts consistently show that gant61 **inhibits beneficial processes for pancreatic cancer**.\n     Inhibition of these processes clearly worsens pancreatic cancer across various studies.\n     No evidence suggests any interaction aligns with supporting the hypothesis.\n  - **Logical Conclusion:**\n     Since gant61 inhibits beneficial processes, and inhibition of these processes worsens pancreatic cancer, the hypothesis is clearly refuted by strong, consistent evidence.\n  - **Scoring:**\n     The interaction does not align with supporting the hypothesis.\n     **Assigned Score:** **-2**\n\nYour goal is to determine the degree of support for the hypothesis:\n\ngant61 treats pancreatic cancer.\n\n**Instructions:**\n\n1. **Review each abstract** to understand how pancreatic cancer and gant61 might be interconnected based on the available information.\n2. **Analyze the presence and implications** of the interaction between pancreatic cancer and gant61 in the context of the hypothesis.\n3. **Carefully assess whether the interaction is beneficial or detrimental** to the proposed outcome in the hypothesis.\n4. **Synthesize the findings from multiple texts**, considering how the pieces fit together to support or refute the hypothesis: gant61 treats pancreatic cancer..\n5. **Provide a justification for your scoring decision** based on the analysis. **Explain your reasoning step-by-step** in terms understandable to an undergraduate biochemist. Focus on:\n   - **Explaining the logical connections and the directionality of relationships.**\n   - **Determining whether the interaction supports or contradicts the hypothesis**, using evidence and logical inferences.\n   - **Assessing if the interaction is beneficial or detrimental** to the proposed outcome.\n6. **Be vigilant for any evidence that contradicts or challenges the hypothesis**. Address any contradictions explicitly in your reasoning.\n7. **Verify any assumptions about the roles and effects** of pancreatic cancer and gant61 as presented in the abstracts. **Avoid inferring effects not supported by the texts**.\n8. In your final assessment, **explicitly cite the scoring guideline** that corresponds to your conclusion. **Explain why the evidence meets the criteria for that specific score**.\n\n**Note:** Pay close attention to the nature of the interaction between entities. An interaction that activates a harmful process may be detrimental, while inhibition of a beneficial process may also be detrimental. **Consider whether such interaction contradicts the hypothesis**.\n\n**Definitions:**\n\u2022 **Evidence:** Multiple sources agree and provide clear indications supporting a particular interaction and its effects.\n\u2022 **Contradictory Evidence:** Evidence that directly opposes the hypothesis, showing that the proposed mechanism of action does not produce the expected outcome.\n\n**Checklist Before Finalizing Your Response:**\n\u2022 Have you **addressed whether the interaction supports or contradicts the hypothesis**?\n\u2022 Have you **assessed if the interaction is beneficial or detrimental**?\n\u2022 Have you **explicitly cited the scoring guideline** that matches your conclusion?\n\u2022 Have you **explained why the evidence meets the criteria** for the assigned score?\n\n**Format your response as:**\n\nScore: \\[Number\\] Point(s) - Reasoning: \\[Reasoning\\]\n\n**Scoring Guidelines:**\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between pancreatic cancer and gant61 **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between pancreatic cancer and gant61 **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between pancreatic cancer and gant61 is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between pancreatic cancer and gant61 may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between pancreatic cancer and gant61 **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AC": [
                    "https://pubmed.ncbi.nlm.nih.gov/19860666/",
                    "https://pubmed.ncbi.nlm.nih.gov/27349387/",
                    "https://pubmed.ncbi.nlm.nih.gov/20024066/",
                    "https://pubmed.ncbi.nlm.nih.gov/24297612/"
                ]
            }
        },
        "ab_relevance": "0.25 (25/100)",
        "bc_relevance": "0.00 (0/9)",
        "ac_relevance": "0.80 (4/5)"
    }
]